Latest Product Pipeline News

Pantoro Gold’s latest infill drilling at Racetrack within the Norseman Project reveals exceptional high-grade continuity, including a spectacular 1,737 g/t gold intercept, underpinning plans to ramp up underground production.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Peak Processing (ASX: PKP) has recorded its first positive Group EBITDA quarter, driven by record beverage production and a significant US manufacturing agreement, marking a pivotal turnaround in FY26.

Evolution Mining (ASX: EVN) is set to acquire Carnaby Resources (ASX: CNB) in a $213 million deal that expands its copper production pipeline near Ernest Henry, leveraging existing infrastructure and latent mill capacity.

Resonance Health (ASX:RHT) closed FY26 with a net operating cash inflow of $2.9 million and completed recruitment for a $13.8 million clinical trial, underpinning a robust contract pipeline and growing net cash position.

PolyNovo has delivered solid FY26 revenue growth of 16.1%, driven by commercial sales expansion and improved manufacturing output, while progressing insurance recovery from its R&D centre fire.

Aeris Resources has secured the critical mining lease for its Constellation Project at Tritton Copper Operations, unlocking the path to production with early construction already underway and waste stripping set for early next year.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

Immuron Limited reported a 6% increase in FY26 sales to AUD 7.7 million, driven by strong gains in Canada and the US despite mixed Australian performance. Marketing initiatives and retail expansion underpin growth.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

Aquirian Limited reported a near tripling of EBITDA to $4.6 million in FY26, driven by a $48 million contract win for its Drillforce subsidiary and expanded production capacity at its Wubin facility.